Gain Therapeutics (GANX) Stock Price, News & Analysis

Gain Therapeutics, Inc. (Nasdaq: GANX) is a clinical-stage biotechnology company focused on the discovery and development of next generation allosteric small molecule therapies. The company is developing drug candidates that modulate the function of disease-related proteins, with an emphasis on neurodegenerative diseases, rare genetic disorders and oncology. Gain Therapeutics is classified in the pharmaceutical preparation manufacturing industry and operates as an emerging growth company listed on The Nasdaq Stock Market LLC.

According to the company, its lead drug candidate GT-02287 is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. GT-02287 is described as an orally administered, brain-penetrant small molecule allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase). GCase can become misfolded and impaired due to mutations in the GBA1 gene or age-related stress factors. In preclinical models of PD, GT-02287 has been reported to restore GCase enzymatic function, reduce endoplasmic reticulum (ER) stress, lysosomal and mitochondrial pathology, aggregated α-synuclein, neuroinflammation and neuronal death, as well as plasma neurofilament light chain (NfL) levels, a biomarker of neurodegeneration. In rodent models of both GBA1-associated PD and idiopathic PD, GT-02287 was shown to rescue deficits in motor function and gait and prevent the development of deficits in complex behaviors such as nesting.

Business focus and therapeutic areas

Gain Therapeutics describes itself as a company leading the discovery and development of allosteric therapies. Its work centers on small molecule modulators that can restore or disrupt protein function. The company reports that GT-02287, beyond Parkinson’s disease, has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. In addition, Gain Therapeutics states that it has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

The company’s approach is based on identifying novel allosteric binding sites on proteins implicated in disease and designing proprietary small molecules that bind these sites to modulate protein function. Gain Therapeutics uses its Magellan™ computational target and drug discovery platform to discover these allosteric sites and identify candidate molecules. According to available information, this platform is intended to accelerate drug discovery and enable the development of disease-modifying treatments for disorders that are considered untreatable or difficult to treat, including neurodegenerative diseases, rare genetic disorders and oncology indications.

Clinical development of GT-02287

GT-02287 has progressed through a Phase 1 study in healthy volunteers and is being evaluated in an ongoing Phase 1b clinical trial in people with Parkinson’s disease with or without a GBA1 mutation. Results from the Phase 1 study in healthy volunteers demonstrated what the company describes as favorable safety and tolerability, plasma and central nervous system exposures in the projected therapeutic range, and target engagement with an increase in GCase activity among those receiving GT-02287 at clinically relevant doses.

The Phase 1b clinical trial is designed with a primary endpoint of evaluating the safety and tolerability of GT-02287 after approximately three months of dosing in people with Parkinson’s disease. Participants have been enrolled across several sites in Australia. Company disclosures indicate that Part 1 of the Phase 1b study involved 90 days of dosing, and an extension phase allows participants to continue treatment with GT-02287 for up to a total of 12 months. Preliminary findings reported by Gain Therapeutics describe GT-02287 as generally well tolerated over 90 days of dosing, with no treatment-emergent serious adverse events observed in the reported data, and plasma exposures within the projected therapeutic range.

Exploratory endpoints in the Phase 1b study include biomarker and functional measures. Gain Therapeutics has reported reductions in glucosylsphingosine (GluSph), a GCase substrate, in cerebrospinal fluid (CSF) of participants with elevated baseline GluSph after 90 days of treatment with GT-02287. The company notes that decreased GluSph in CSF is an indication of increased GCase activity in the brain. It has also reported observations of stabilization or improvement in Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores in some participants after 90 days of dosing, and has characterized these findings as suggesting a disease-modifying or disease-slowing effect consistent with its proposed mechanism of action and preclinical models. These observations are described by the company as early and exploratory.

Preclinical evidence and mechanism of action

Gain Therapeutics has presented preclinical data for GT-02287 in multiple models of Parkinson’s disease. In preclinical studies, GT-02287 has been reported to restore GCase enzymatic function and improve cellular health in neuronal systems. The company has highlighted reductions in ER stress, lysosomal and mitochondrial pathology, aggregated α-synuclein, neuroinflammation and neuronal death, as well as reductions in plasma NfL levels in preclinical PD models following administration of GT-02287.

Additional preclinical work presented by Gain Therapeutics describes GT-02287 as affecting GCase at the level of mitochondria as well as lysosomes. In cultured rat mesencephalic dopaminergic neurons treated with the mitochondrial toxin MPP+, GT-02287 was reported to reduce mitochondrial reactive oxygen species and prevent cytochrome C release, thereby alleviating mitochondrial stress and promoting neuronal survival. In a mouse PD model using α-synuclein pre-formed fibrils, GT-02287 decreased substantia nigral staining for the mitochondrial protein MIRO1, a marker of depolarized mitochondria. In patient-derived fibroblasts carrying a severe GBA1 mutation, GT-02287 increased mitochondrial GCase levels, enhanced mitochondrial complex I activity, and improved mitochondrial membrane potential. Taken together, the company interprets these findings as suggesting that GT-02287 improves mitochondrial function by facilitating GCase trafficking to mitochondria as well as lysosomes.

Research platform and pipeline

Gain Therapeutics’ research and development activities are supported by its Magellan™ computational platform. According to company descriptions, Magellan is used to discover novel allosteric binding sites on disease-related proteins and to identify small molecules that can modulate these targets. This approach is applied across multiple therapeutic areas, including lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has disclosed the existence of multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases and solid tumors, but has not publicly detailed specific candidates beyond GT-02287 in the provided materials.

The company has also reported that its lead Parkinson’s disease program has received funding support early in its development from The Michael J. Fox Foundation for Parkinson’s Research, The Silverstein Foundation for Parkinson’s with GBA, and the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research program and Innosuisse – Swiss Innovation Agency. These funding sources are cited by Gain Therapeutics as external support for its research in GCase modulation and Parkinson’s disease.

Corporate status and regulatory filings

Gain Therapeutics, Inc. is incorporated in Delaware and its common stock, with a par value of $0.0001 per share, is registered under the symbol GANX on The Nasdaq Stock Market LLC. The company has identified itself as an emerging growth company in its filings with the U.S. Securities and Exchange Commission (SEC). Recent Form 8-K filings describe activities such as presentation of clinical and preclinical data for GT-02287, updates on the Phase 1b clinical study, financial results, and corporate actions including an increase in authorized shares of common stock.

The company’s SEC filings and press releases emphasize that statements about clinical development, potential therapeutic benefits, and future plans are forward-looking and subject to risks and uncertainties. Investors typically review Gain Therapeutics’ annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K for detailed information on operations, risk factors, clinical progress and financial condition.

Geographic operations

According to previously reported information, Gain Therapeutics operates in Switzerland, Spain, the United States and Australia. Clinical trial activity for GT-02287 has included multiple sites in Australia, and corporate communications are issued from Bethesda, Maryland. These geographies reflect both the company’s research footprint and its clinical development activities.